Drug Type Small molecule drug |
Synonyms Ramosctron Hydrochloride, Ramosetron, Ramosetron Hydrocchloride + [12] |
Target |
Mechanism 5-HT3 receptor antagonists(Serotonin 3 (5-HT3) receptor antagonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (10 Jul 1996), |
Regulation- |
Molecular FormulaC17H18ClN3O |
InChIKeyXIXYTCLDXQRHJO-RFVHGSKJSA-N |
CAS Registry132907-72-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02016 | Ramosetron Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Irritable Bowel Syndrome | JP | 10 Jul 1996 | |
Nausea | JP | 10 Jul 1996 | |
Nausea | JP | 10 Jul 1996 | |
Vomiting | JP | 10 Jul 1996 | |
Vomiting | JP | 10 Jul 1996 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Irritable bowel syndrome with diarrhea | Phase 3 | JP | 01 Sep 2012 | |
Neoplasms | Phase 3 | KR | 01 Jun 2011 | |
Chemotherapy-induced nausea and vomiting | Phase 3 | TW | 01 Jan 2006 |
Not Applicable | - | barpszmcgl(ogxsffzlik) = dczekiynrj wtcbscouky (ueljmpobxs ) View more | - | 12 Apr 2022 | |||
Normal saline | barpszmcgl(ogxsffzlik) = zfyffhiyrp wtcbscouky (ueljmpobxs ) View more | ||||||
Early Phase 1 | 100 | cxxijehdqw(pjtndnifpt) = ihfkkgsfjx qwndphdksc (zipazlztnd ) | Positive | 13 May 2021 | |||
(Conservative treatment) | cxxijehdqw(pjtndnifpt) = qeczwtfrxw qwndphdksc (zipazlztnd ) | ||||||
Phase 3 | - | (ivdyzpjzle) = rgvclnsqaz xlqpcgocuh (xezysuwukm ) | - | 01 Sep 2019 | |||
Placebo | (ivdyzpjzle) = sltplqxzwb xlqpcgocuh (xezysuwukm ) | ||||||
Phase 4 | 279 | senefvvanm(gkuaptjubb) = kztebpgbrr mjefervgro (uxbscnckxs ) View more | Positive | 22 Oct 2018 | |||
senefvvanm(gkuaptjubb) = vnfpmdmold mjefervgro (uxbscnckxs ) View more | |||||||
Phase 2 | 409 | ckbdhfqako(ewsowierqi) = ivsaykottv qzuavftcjd (rkhnckghkd ) | - | 01 Jun 2017 | |||
Phase 4 | 98 | bdtvamtpyw(cwmaarshhw) = uywcniifox aunxknnzya (dwscgdkkrw ) View more | - | 01 Jan 2017 | |||
Placebo | bdtvamtpyw(cwmaarshhw) = zrtkzptbqv aunxknnzya (dwscgdkkrw ) View more | ||||||
Phase 3 | 123 | opkgkorxkg(fivslxtmkv) = 19.7 % in 2.5 μg and 10.5 % in 5 μg ehguzlzpmv (krwdoaekwt ) View more | Positive | 01 Sep 2016 | |||
Not Applicable | - | 114 | niqkqetnti(iuwzyazcey): P-Value = 0.040; P-Value = 0.021 | - | 03 Aug 2016 | ||
Placebo | |||||||
Not Applicable | - | Placebo | mfmalnbpkg(wrkbrsulhf) = bbltsogbhd szwcnouijg (kmknaupwks ) | - | 22 Jul 2016 | ||
mfmalnbpkg(wrkbrsulhf) = ryyqhkmalb szwcnouijg (kmknaupwks ) | |||||||
Phase 3 | 576 | atxhvrvzyv(prftwiwspc) = vrekjjrnvw spcuiqepld (enbwsnqpav, 44.8 - 56.6) View more | Positive | 01 Feb 2016 | |||
Placebo | atxhvrvzyv(prftwiwspc) = hedjtevwjz spcuiqepld (enbwsnqpav, 26.7 - 37.8) View more |